Insights
Articles
Brand Access Marketplace Dynamics: Autoimmune
This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective…
5 Trends in Digital Medicine to Watch For
We Are Uniquely Positioned To Deliver EVERSANA is uniquely positioned to follow the trends and introduce new models and strategies to maximize the value of pharmaceutical products through Digital Medicine Solutions and Execution. Digital Solutions…
Patient Engagement During the COVID-19 Pandemic
As the public health pandemic spreads, EVERSANA has identified challenges facing clinical trial participation, and how these challenges will impact patients now and following the COVID-19 pandemic. […] Supporting patients and providing them with valuable information…
The 2020 Playbook Addendum: Augment Your Frontline to Boost Sales Momentum
In the midst of a global pandemic, the role of commercial field teams evolved right before our eyes. Digital sales aids and tele-detailing are now mandatory sales tactics in a virtual Provider-Rep engagement. Now that field…
What Canada’s IRP Changes Could Mean for the Industry
Last August, Canada’s Patented Medicine Prices Review Board (PMPRB) announced a set of amendments for its regulatory measures, in a bid to strengthen and modernize the country’s pricing framework for patented drugs. Following the initial proposal…
Pricentric ONE Newsletter | May 2020
Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!
Healthcare Pivot: Digital Medicine Delivers During A Global Crisis – Reviewing Commercial Pathways
In February 2020, healthcare as we knew it changed. The industry began waging an aggressive war with an unknown virus beginning to overwhelm hospitals on a global scale. We immediately recognized that we needed to do…
Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
Posted by Craig Ornstein, PhD, Dr. Richard Stefanacci, Jamey Hardesty, MPH, Uttama Rath, PhD on June 5, 20206/5/20
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug Administration (FDA)-approved oncolytic biosimilars in the…
PharmaVOICE Connected Health Showcase
IF I COULD ONLY ASK TWO QUESTIONS, THE FIRST WOULD BE: What is your data integration and analytics platform strategy? As the industry continues its shift to a patient-centric, value-based model of care, it is critical…
PharmaVOICE Showcase on Real-World Evidence
“The complete product lifecycle requires the use of real world evidence to achieve launch success and optimal market access.” As manufacturers develop new innovative medicines and healthcare interventions that disrupt traditional treatment paradigms, it’s critical they…